Raúl Ortiz-de-Lejarazu , Borja Quiroga Gili , Alberto López García
{"title":"西班牙免疫力低下患者中 COVID-19 变体 omicron 的负担：系统回顾","authors":"Raúl Ortiz-de-Lejarazu , Borja Quiroga Gili , Alberto López García","doi":"10.1016/j.medcle.2024.09.001","DOIUrl":null,"url":null,"abstract":"<div><div>After the COVID-19 pandemic, the Omicron variant of the SARS-CoV-2 virus became the dominant lineage in Spain in 2022. Although it possesses a milder pathogenicity than previous variants, it still poses a high risk of causing severe COVID-19 for immunocompromised populations.</div><div>A systematic review was conducted to assess the burden of COVID-19 in Spain among immunocompromised patients during the Omicron predominance (1/04/2022–1/04/2023), using PubMed, Cochrane Library, and EPICOVIDEHA between May and July 2023.</div><div>The search retrieved 217 articles, of which a total of 5 were included. Upon analysis, it was observed that immunocompromised patients during the Omicron lineage predominance continue to exhibit higher rates of hospitalizations, ICU admissions, and mortality compared to the general population affected by COVID-19. Although the pandemic has ended, the risk persists for immunocompromised individuals.</div></div>","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":"163 7","pages":"Pages 347-359"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Burden of COVID-19 variant omicron in immunocompromised patients in Spain: Systematic review\",\"authors\":\"Raúl Ortiz-de-Lejarazu , Borja Quiroga Gili , Alberto López García\",\"doi\":\"10.1016/j.medcle.2024.09.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>After the COVID-19 pandemic, the Omicron variant of the SARS-CoV-2 virus became the dominant lineage in Spain in 2022. Although it possesses a milder pathogenicity than previous variants, it still poses a high risk of causing severe COVID-19 for immunocompromised populations.</div><div>A systematic review was conducted to assess the burden of COVID-19 in Spain among immunocompromised patients during the Omicron predominance (1/04/2022–1/04/2023), using PubMed, Cochrane Library, and EPICOVIDEHA between May and July 2023.</div><div>The search retrieved 217 articles, of which a total of 5 were included. Upon analysis, it was observed that immunocompromised patients during the Omicron lineage predominance continue to exhibit higher rates of hospitalizations, ICU admissions, and mortality compared to the general population affected by COVID-19. Although the pandemic has ended, the risk persists for immunocompromised individuals.</div></div>\",\"PeriodicalId\":74154,\"journal\":{\"name\":\"Medicina clinica (English ed.)\",\"volume\":\"163 7\",\"pages\":\"Pages 347-359\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicina clinica (English ed.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2387020624004133\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina clinica (English ed.)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2387020624004133","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Burden of COVID-19 variant omicron in immunocompromised patients in Spain: Systematic review
After the COVID-19 pandemic, the Omicron variant of the SARS-CoV-2 virus became the dominant lineage in Spain in 2022. Although it possesses a milder pathogenicity than previous variants, it still poses a high risk of causing severe COVID-19 for immunocompromised populations.
A systematic review was conducted to assess the burden of COVID-19 in Spain among immunocompromised patients during the Omicron predominance (1/04/2022–1/04/2023), using PubMed, Cochrane Library, and EPICOVIDEHA between May and July 2023.
The search retrieved 217 articles, of which a total of 5 were included. Upon analysis, it was observed that immunocompromised patients during the Omicron lineage predominance continue to exhibit higher rates of hospitalizations, ICU admissions, and mortality compared to the general population affected by COVID-19. Although the pandemic has ended, the risk persists for immunocompromised individuals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
